Standout Papers

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Pa... 1997 2026 2006 2016 1.5k
  1. Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (2004)
    David H. Johnson, Louis Fehrenbacher et al. Journal of Clinical Oncology
  2. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. (1997)
    Robert H. Collins, Ofer Shpilberg et al. Journal of Clinical Oncology
  3. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer (2000)
    Fadlo R. Khuri, John Nemunaitis et al. Nature Medicine
  4. Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies (2001)
    Manuel Hidalgo, Lillian L. Siu et al. Journal of Clinical Oncology
  5. Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer (2006)
    Eric J. Small, Paul F. Schellhammer et al. Journal of Clinical Oncology
  6. Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer (2000)
    Alan B. Sandler, John Nemunaitis et al. Journal of Clinical Oncology
  7. Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer (2009)
    Celestia S. Higano, Paul F. Schellhammer et al. Cancer
  8. Ovarian Cancer Immunotherapy and Personalized Medicine (2021)
    Susan Morand, Monika Devanaboyina et al. International Journal of Molecular Sciences

Immediate Impact

8 by Nobel laureates 15 from Science/Nature 96 standout
Sub-graph 1 of 19

Citing Papers

CAR T therapy beyond cancer: the evolution of a living drug
2023 StandoutNature
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
11 intermediate papers

Works of John Nemunaitis being referenced

Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer
2017
Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma.
2015
and 3 more

Author Peers

Author Last Decade Papers Cites
John Nemunaitis 13692 9640 5907 538 24.9k
Martin Gore 14140 12791 3567 377 29.0k
Dario C. Altieri 8880 22122 5768 255 30.8k
Mark Raffeld 13976 6539 7669 423 26.9k
Luis A. Díaz 14224 12867 3523 413 39.4k
Francesco M. Marincola 12036 9272 15130 487 27.1k
Robert D. Cardiff 10620 14681 3128 332 25.0k
Soldano Ferrone 13716 10404 21514 858 34.4k
Robert S. Kerbel 16351 24243 5451 398 41.1k
Mario P. Colombo 8351 7488 14887 349 23.8k
George Klein 19900 9988 10598 793 35.7k

All Works

Loading papers...

Rankless by CCL
2026